Skip to Content
Merck
CN
  • Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells.

Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells.

Autophagy (2012-12-18)
Shan Zhu, Lizhi Cao, Yan Yu, Liangchun Yang, Minghua Yang, Ke Liu, Jun Huang, Rui Kang, Kristen M Livesey, Daolin Tang
ABSTRACT

IFN1@ (interferon, type 1, cluster, also called IFNα) has been extensively studied as a treatment for patients with chronic myeloid leukemia (CML). The mechanism of anticancer activity of IFN1@ is complex and not well understood. Here, we demonstrate that autophagy, a mechanism of cellular homeostasis for the removal of dysfunctional organelles and proteins, regulates IFN1@-mediated cell death. IFN1@ activated the cellular autophagic machinery in immortalized or primary CML cells. Activation of JAK1-STAT1 and RELA signaling were required for IFN1@-induced expression of BECN1, a key regulator of autophagy. Moreover, pharmacological and genetic inhibition of autophagy enhanced IFN1@-induced apoptosis by activation of the CASP8-BID pathway. Taken together, these findings provide evidence for an important mechanism that links autophagy to immunotherapy in leukemia.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Caspase-3 Cellular Activity Assay Kit
Sigma-Aldrich
MISSION® esiRNA, targeting human ULK1